10x Genomics (NASDAQ:TXG – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
Insider and Institutional Ownership
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 46.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares 10x Genomics and Champions Oncology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $642.82 million | 12.49 | -$43.54 million | ($0.59) | -104.46 |
| Champions Oncology | $59.42 million | 1.13 | -$1.17 million | ($0.08) | -60.12 |
Champions Oncology has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Champions Oncology, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Profitability
This table compares 10x Genomics and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -12.18% | -9.33% | -7.30% |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for 10x Genomics and Champions Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 1 | 12 | 5 | 0 | 2.22 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
10x Genomics currently has a consensus target price of $68.00, suggesting a potential upside of 10.34%. Given 10x Genomics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe 10x Genomics is more favorable than Champions Oncology.
Summary
10x Genomics beats Champions Oncology on 8 of the 14 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
